Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice

Autor:	Fabíola Z. Mónica, Edson Antunes, Tuany Z. Candido, Carmem Valgas da Silva, Mariana G. de Oliveira, Fábio H. Silva, Eduardo C. Alexandre, Fabiano B. Calmasini
Rok vydání:	2016
Předmět:	Male 0301 basic medicine Beta-3 adrenergic receptor medicine.medical_specialty Carbachol Urology Urinary system media_common.quotation_subject Urinary Bladder 030232 urology & nephrology Mice Obese Urination Adrenergic beta-3 Receptor Agonists Mice 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Cyclic AMP medicine Animals Cyclic adenosine monophosphate Obesity media_common medicine.diagnostic_test Urinary Bladder Overactive business.industry Body Weight Muscle Smooth Cyclic Nucleotide Phosphodiesterases Type 4 Mice Inbred C57BL Thiazoles 030104 developmental biology Endocrinology chemistry Acetanilides Neurology (clinical) Lipid profile Mirabegron business Muscle Contraction medicine.drug Lipoprotein
Zdroj:	Neurourology and Urodynamics. 36:1511-1518
ISSN:	0733-2467
Popis:	Aims To evaluate the effects of the beta-3 adrenoceptor agonist, mirabegron in a mouse model of detrusor overactivity induced by obesity. Methods C57BL/6 male mice were fed with standard chow or high-fat diet for 12 weeks. Lean and obese mice were treated orally with mirabegron (10 mg/kg/day) from the last 2 weeks of diet. Cystometric evaluations, functional assays, protein expression for phosphodiesterase type 4 (PDE4), and cyclic adenosine monophosphate (cAMP) measurement were carried out. Results In obese mice the body weight, epididymal fat mass, fasting glucose, and low-density lipoprotein (LDL) levels were higher (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e3759e6d4041e58a7edfb7274ff15df https://doi.org/10.1002/nau.23171 Zobrazit plný text záznamu Plný text